AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY, as the first and only T-cell engaging bispecific antibody for the...
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, announced a global out-license agreement with AstraZeneca...
